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 Movement disorders comprise hyperkinetic involuntary 
movements (eg tremor, myoclonus, tics, dystonia and 
chorea) and hypokinetic (parkinsonism) disorders. Tics are 
cardinal features of primary tic disorders encompassing 
Tourette syndrome (TS), but are also found in some 
neurodegenerative conditions and may be induced by 
psychoactive substances. The ﬁrst line treatment for tics 
is pharmacological (mainly dopamine receptor blockers or 
alpha-2 adrenergic agonists) and behavioural. Dystonia 
and chorea syndromes are considerably heterogeneous 
in aetiology, and age at onset, body distribution of the 
movement disorder, accompanying neurological motor and 
non-motor features, and systemic manifestations are all 
important to reach a correct aetiological diagnosis. While 
symptomatic pharmacological treatment remains the 
mainstay of treatment for choreas, deep brain stimulation 
surgery has a well-deﬁned place in the management of 
medically refractory dystonia. 
 Introduction 
 Movement disorders comprise hyperkinetic involuntary 
movements (eg tremor, myoclonus, tics, dystonia and chorea) 
and hypokinetic (parkinsonism) disorders. 1 Because of the 
complex aetiology of movement disorder syndromes, accurate 
phenomenological characterisation of the clinical features of 
these syndromes is an important first step to plan the correct 
diagnostic work-up and guide further management and referral 
to the appropriate neurology services. 
 Here, we provide a brief overview of three subtypes of 
hyperkinetic disorders (tics, dystonia and chorea), discussing 
their clinical diagnosis and therapeutic approach. Despite 
the lack of disease-modifying treatment for the majority of 
these neurological disorders, an effort to improve diagnostic 
acumen remains paramount for the provision of prognosis to 
the patients and their families, and for patient recruitment in 
future therapeutic trials. 
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 What is new in tics, dystonia and chorea? 
 Tics 
 Clinical presentation 
 Tics are repetitive and patterned movements or phonic 
utterances that appear out of context, may be partially 
suppressed under volition, and are often preceded by 
uncomfortable urges that are temporarily relieved by tic 
production. Tics are the defining feature of neurodevelopmental 
chronic tic disorders, among which Tourette syndrome (TS) 
remains the most clinically relevant primary tic disorder. 
Key points
 Tourette syndrome exhibits an important comorbidity with 
attention-deﬁcit/hyperactivity disorder or obsessive compulsive 
disorder (72%), mood, anxiety and disruptive behaviour 
disorders (each approximately 30%). 
 Several randomised controlled trials and meta-analyses support 
alpha-2 adrenergic agonists and dopamine receptor blockers as 
ﬁrst line treatment for tics. 
 Dystonic movements and postures can occur at rest but are 
typically aggravated by voluntary movement and, in some 
forms of dystonia, is almost exclusively triggered by speciﬁc 
complex motor actions (eg writing dystonia, musician’s 
dystonia). 
 Chemodenervation with botulinum neurotoxins is the most 
effective and widely available treatment for segmental/focal 
dystonias, whereas deep brain stimulation surgery has gained 
an important role in the management of medically refractory 
dystonia. 
 The different causes of chorea may be recognised based on 
course (acute/subacute or chronic) and body distribution (focal, 
segmental, unilateral, generalised). 
 The pharmacological treatment of chorea involves D2 
dopamine receptor blockers, tetrabenazine and antiepileptic 
agents (mainly carbamazepine and valproic acid). 
 KEYWORDS: Chorea, diagnosis, dystonia, hyperkinetic 
movement disorders, tics, treatments  ■
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According to the recent Diagnostic and Statistical Manual of 
Mental Disorders V (DSM-V) criteria, TS is diagnosed by the 
presence of motor and vocal (or phonic) tics, which manifest 
before the age of 18 for more than 12 months in the absence of 
secondary causes. 2 Tics are less commonly secondary to other 
conditions or causative factors (Box  1 ). 3 
 In a meta-analysis of prevalence data from 1985 to 2011, 
studies applying a school-based assessment yielded a 
combined prevalence of 0.77% for TS, 1.61% for chronic 
tic disorders, 2.99% for transient tic disorders, and 2.82% 
for the ‘all tic disorders’ category in the population up to 16 
years of age. 4 2015 population-based data have confirmed 
that only about 15% of TS patients do not suffer from any 
other psychiatric comorbidity, with the majority of patients 
affected by attention-deficit/hyperactivity disorder (ADHD) or 
obsessive compulsive disorder (72% cumulatively), or mood, 
anxiety and disruptive behaviour (impulsive behaviours, rage 
attacks) disorders (each approximately 30%). 5 This striking 
comorbidity profile should be taken into account during 
the assessment of TS patients, in order to identify treatment 
priorities in each individual patient. 
 Tics are now viewed as the result of altered inhibitory control 
mechanisms modulating action selection. Importantly, tics 
are highly influenced by sensory, cognitive and emotional 
inputs, suggesting dysfunctional crosstalk between all 
three of the main cortico-basal ganglia circuits (motor, 
associative and limbic). Recent advances coming from 
neurophysiological, 6 imaging (magnetic resonance imaging 
(MRI) and magnetoencephalography), 7,8 neurobiological 
(animal models) 9 and neuropathological studies confirmed 
the involvement of dysfunctional inhibitory control at the level 
of both inhibitory projection neurons or interneurons in the 
striatum and cortical microcircuits. A relationship has been 
found between vocal tics and abnormal connectivity of the 
ventral striatum within cortico-subcortical limbic circuits in a 
primate model. Importantly, post-mortem studies documented 
reduced numbers and function of striatal interneurons in 
adults with TS. 10 
 Treatment 
 Therapeutic algorithms like those published by the 
European Society for the Study of Tourette Syndrome (Fig  1 ) 
identify three main decisional stages in the treatment of 
tics. After diagnosis and comprehensive assessment, a more 
active intervention for tics (ie beyond psychoeducation) is 
necessary only when tics impact on social and academic 
functioning, are stigmatising, or potentially physically 
harmful. 11 Once a decision to treat tics more actively is 
taken, the next step is to decide between behavioural and 
pharmacological treatment. 
 A behavioural approach, like the Comprehensive Behavioural 
Intervention for Tics, which applies habit reversal training, 
is supported by high quality trials on youths and adults with 
TS. 12 Other approaches, such as exposure response prevention 
and cognitive psychophysiological models, still require testing 
in higher quality trials, and the efficacy of their combination 
with pharmacological treatments remains to be investigated. 
Moreover, behavioural treatments may be difficult to apply 
in younger children (below age 10) or in patients with severe 
comorbid ADHD. 13 
 Box 1.  Secondary causes of tics 
 Neurodevelopmental disorders 
>  Mental retardation
>  Autistic spectrum disorders (including Asperger syndrome)
>  Rett syndrome
>  Genetic and chromosomal abnormalities
>  X-linked mental retardation ( MRX23 )
>  Albright hereditary osteodystrophy
>  Duchenne muscular dystrophy
>  Factor VIII hemophilia
>  Fragile X syndrome
>  Lesch-Nyhan syndrome
>  Triple X and 9p mosaicism
>  47 XXY karyotype
>  Partial trisomy 16
>  9p monosomy
>  Beckwith-Wiedemann syndrome
>  Tuberous sclerosis
>  Congenital adrenal hyperplasia due to 21-hydroxylase 
deficiency
>  Phenylketonuria
>  Corpus callosum dysgenesis
>  Craniosynostosis
>  Klinefelter syndrome
>  Neurofibromatosis
>  Developmental stuttering
 Acute brain lesions 
>  Post-traumatic
>  Vascular
>  Infectious
>  Varicella-zoster virus
>  Herpes simplex encephalitis
>  Mycoplasma pneumoniae 
>  Lyme disease
 Post-infectious 
>  Sydenham’s chorea
>  Pediatric autoimmune neuropsychiatric disorder associated 
with streptococcal infections (PANDAS)
 Neurodegenerative diseases 
>  Huntington disease
>  Neuroacanthocytosis syndromes
>  Neurodegeneration with brain iron accumulation
 Other systemic diseases 
>  Behçet’s syndrome
>  Antiphospholipid syndrome
 Peripheral trauma 
 Medications and toxins 
>  Amphetamines, cocaine, heroin, methylphenidate, pemoline, 
antipsychotics (tardive tics), antidepressants, antiepileptics 
(carbamazepine, phenytoin, phenobarbital, lamotrigine), L-dopa
 Functional tic-like jerks 
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 Several randomised controlled trials and meta-analyses 
support alpha-2 adrenergic agonists and dopamine receptor 
blockers as first line agents for the treatment of tics. The 
former group of drugs (guanfacine – unavailable in several 
European countries – and clonidine) appears to be effective 
against tics predominantly in TS patients with comorbid 
ADHD. 14 Among dopamine receptor blockers, aripiprazole, 
risperidone, pimozide and haloperidol were confirmed to 
be effective in meta-analyses, although the poor tolerability 
of first generation antipsychotics (pimozide, haloperidol) 
strongly limits their routine use. 15 Although not supported 
by a similar degree of evidence quality, fluphenazine and 
benzamides are often favoured because of their better 
tolerability profile than a non-antipsychotic dopamine 
depletor like tetrabenazine. Botulinum toxin may have 
great utility in cranial and cervical motor tics, as well as in 
vocal tics. 
 Patients with severe, highly disabling tics who are 
unresponsive to first line interventions are now more 
and more frequently considered for neuromodulation 
strategies, such as deep brain stimulation (DBS). More than 
130 patients with TS have been treated with DBS worldwide, 
with less than a dozen cases under the age of 18 years. 16 In 
patients under 18 years of age, DBS should be considered only 
in those whose psychiatric comorbidities are stable and who 
do not present with suicidality or high risk of aggressiveness 
directed against others. Although priority anatomical targets 
are still being debated, crossover sham-controlled trials 
support the efficacy of globus pallidus internus (limbic 
portion particularly) 17 and centromedian/parafascicularis 
nuclei stimulation, 18 with an acceptable short- and medium-
term adverse effect profile. 
 Dystonia 
 Clinical presentation 
 Dystonia is a movement disorder characterised by sustained 
muscle contractions, which frequently cause abnormal postures 
(tonic component) or repetitive movements (phasic component). 
The typical clinical features of dystonic contractions are marked 
directionality, long duration, and simultaneous involvement 
of agonist and antagonist muscles. 19 Dystonic movements can 
less commonly be more rapid and have a rhythmic pattern, 
resembling a tremor. However, in most cases, dystonic tremor 
may show an evident directionality, unlike the typical sinusoidal 
oscillations of other forms of tremor. 20 
 Dystonic movements and postures can occur at rest but are 
typically aggravated by voluntary movement. In some forms, 
dystonia is almost exclusively triggered by specific complex 
motor actions performed with the same body part (eg writing 
dystonia, musician’s dystonia). Dystonic contractions within 
a specific body region can also be triggered by voluntary 
movements occurring at distant segments (overflow 
phenomena). 21 A rare phenomenon is the suppression of 
dystonia during voluntary movements (paradoxical dystonia) 
and involves the facial muscles. 19,21 
 Gestes antagonistes (also known as ‘sensory tricks’) are 
typical features of dystonic movements and indicate temporary 
reduction in the severity of dystonia by using an alternative 
motor action, which often conveys tactile or proprioceptive 
stimulation; typical gestes include touching the chin or the neck 
in cervical dystonia. 22 
 The clinical classification of dystonia has been recently 
revised, and comprises two main axes: clinical characteristics 
and aetiology (Fig  2 ). 23 
Tics
Psychoeducaon
Monitoring
No indicaon
for treatment
no
no
Indicaon for
treatment with preference
for behavioural treatment
Sll indicaon to
treatment
Indicaon for
treatment with preference
for pharmacological treatment
Stage 1
Stage 3
Stage 2
Symptom-focused
behavioural therapy
Pharmacotherapy and
behavioural therapy
Polypharmacotherapy
Other treatments
(eg DBS)
Pharmacotherapy
 Fig 1.  Therapeutic algorithms for 
treatment of tic disorders. 
Decision tree for the treatment of 
tics (speciﬁ cally focused on 
Tourette syndrome and other 
primary tic disorders). 11  DBS = deep 
brain stimulation. 
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 Isolated (formerly known as primary) dystonia encompasses 
all those conditions in which dystonia is the sole relevant 
clinical feature, with the exception of associated tremor. 
This is a genetically heterogeneous group of disorders. Early 
onset forms (ie age at onset <26 years) become frequently 
generalised and are associated with  TOR1A (DYT1, without 
cranio-cervical involvement) and  THAP1 (DYT6, with 
cranio-cervical involvement) gene mutations. More than 
five other potentially causative genes have been described in 
the last 3 years, which are also associated with adult-onset 
(focal) forms. However, their role in aetiology and diagnosis 
is still under investigation. 24 Combined dystonia syndromes 
include myoclonus-dystonia syndromes (also genetically 
heterogeneous) and dystonia-parkinsonism syndromes; 
the latter group includes dopa-responsive forms and 
heredodegenerative diseases that include the complex family 
of neurodegeneration with brain iron accumulation disorders 
(Box  2 ). 
 Treatment 
 The mainstay treatment for isolated dystonia and the 
majority of secondary dystonias remains pharmacological, 
even though early DBS for monogenic forms of isolated 
generalised dystonia is now extensively applied. 
Anticholinergic drugs (eg trihexyphenidyl) remain first 
line agents for multifocal or generalised dystonias, and 
their dose should be titrated gradually to minimise side 
effects, particularly dry mouth, gastrointestinal upset, 
urinary retention and confusion. 25 Muscle relaxants such 
as baclofen (available also in intrathecal pump infusion 
formulation) and clonazepam can be helpful when spasticity 
or tremor, respectively, are associated with dystonia; lethargy, 
dizziness and confusion may be associated with these drugs. 
Dopamine-depleting drugs such as tetrabenazine may be 
helpful in a smaller proportion of cases. L-dopa in small 
doses (50–200 mg) represents the first line treatment for 
dopa-responsive dystonias and, given the costs of genetic 
screening for these forms of dystonia, an empiric trial of 
L-dopa is usually offered to all patients with early onset 
dystonia in whom there is no evidence of neurodegeneration 
or brain structural lesions. 26 Chemodenervation with 
botulinum neurotoxins (three forms of botulinum toxin A 
and one of botulinum toxin B are available in the UK) is a 
very effective and widely available treatment for segmental/
focal dystonias in which the topography of the muscles 
involved can be determined. 27 Electromyographic and 
ultrasound guidance techniques have greatly advanced 
recently for those body regions, like upper and lower limbs, 
in which the superficial injection approach is hindered by 
the complexity of anatomical localisation of the muscles 
contributing to dystonia. 25,28 
 DBS is considered for highly disabling, medically refractory 
dystonias. DBS of the globus pallidus internus (GPi) has been 
shown to be very effective for the treatment of DYT1 dystonia 
and, to a slightly lesser extent, for non-DYT1, early-onset 
generalised dystonias. A 35–45% improvement in severity was 
also reported for refractory cervical dystonia treated with GPi 
DBS. There is a less quality evidence to support DBS of the 
subthalamic nucleus in cervical dystonia and for GPi DBS of 
secondary dystonias or other focal dystonias (cranial, upper 
limb). 29 The full benefit of GPi DBS in dystonia is usually 
achieved after several months, with stable efficacy for more 
than 5 years. 30,31 
Clinical characteriscs
Aeology
Age at onset
Infancy (birth to 2 years)
Childhood (3–12 years)
Adolescence (13–20 years)
Early adulthood (21–40 years)
Late adulthood (>40 years)
Focal
Segmental
Mulfocal
Generalised
Hemidystonia
Isolated Combined 
with other 
MDS
Other
neurological 
or systemic 
manifestaon
Body distribuon Temporal paern Associate features
Disease course
• Stac
• Progressive
Variability
• Persistent
• Acon-speciﬁc
• Diurnal
• Paroxysmal
Nervous system pathology Inherited or acquired
Evidence of degeneraon
Evidence of structural lesions
No evidence of degeneraon or 
structural lesions Autosomal dominant
Autosomal recessive
X-linked recessive
Michondrial
Perinatal brain injury
Infecon
Drug
Toxic
Vascular
Neoplasc
Brain injury
Funconal (psychogenic)
Sporadic
Familial
Inherited Acquired Idiopathic
 Fig 2.  Classiﬁ cation of 
dystonia . Dystonia is currently 
 classiﬁ ed according to two axes: 
clinical characteristics and 
aetiology. Clinical characteris-
tics include age at onset, body 
distribution, temporal pattern 
and associated features. The ae-
tiological axis refers to presence 
of nervous system pathology 
and whether these are inherited, 
acquired or idiopathic in nature 
(from Martino D, Espay AJ, 
 Fasano A, Morgante F.  Disorders 
of movement: a guide to diag-
nosis and treatment . Heidelberg: 
Springer-Verlag, 2016).  MDS = 
movement disorders. 
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 Chorea 
 Clinical presentation 
 Chorea is a movement disorder characterised by rapid, 
purposeless, non-stereotyped movements flowing randomly 
from one part of the body to another. 32 Chorea is caused by 
a multitude of conditions with different pathophysiological 
mechanisms. In the majority of cases, the clinical context in 
which chorea develops is the key to defining its aetiology. The 
different causes of chorea may be recognised based on course 
(acute/subacute, ie reaching a peak of severity within days/
weeks, or chronic, ie gradually progressing over months or 
years) and body distribution (focal, segmental, unilateral, 
generalised). An updated list of the different aetiologies of 
chorea and relative diagnostic work-up is provided in  Table S1. 
 Within the rubric of acute/subacute chorea, the spectrum 
of immune-mediated causes of chorea has broadened 
extensively to include a vast group of autoantibody-induced 
encephalopathies (such as those associated with anti-LGI1, 
anti-GAD65, anti-CASPR2, anti-GABA-B receptor antibodies, 
in addition to the choreiform movements documented 
in anti-NMDA-receptor antibody-related encephalitis). 33 
Furthermore, there is increasing interest in the behavioural 
and cognitive aspects of the prototype of immune-mediated 
choreas, ie Sydenham’s (or rheumatic) chorea (SC). 34 Executive 
dysfunction, obsessive-compulsive disorder, mood disorders, 
anxiety, ADHD, tic disorders and (rarely) psychosis are 
important comorbidities in patients with SC. 33 
 Among chronic or progressive chorea, Huntington’s disease 
(HD) remains the most frequent cause. This is an autosomal 
dominant trinucleotide repeat disorder related to the  IT15 
gene coding for the protein huntingtin. 35 Usually, chorea is 
the prominent movement disorder of adult-onset HD, whereas 
juvenile HD (Westphal variant) typically presents with an 
akinetic-rigid syndrome and progresses more rapidly. 36 
Personality changes, depression, hostility and/or increased 
interpersonal sensitivity, obsessive-compulsive symptoms, 
phobias and anxiety appear early in the course of the illness. As 
 Box 2.  Secondary dystonias 
 Non-degenerative combined dystonia syndromes 
>  Dopa-responsive dystonia: results from genetic defects in 
enzymes that are involved in the biosynthesis of dopamine; 
the most common condition is autosomal dominant GTP 
cyclohydrolase 1 deficiency (Segawa disease)
>  Rapid onset dystonia-parkinsonism ( ATP1A3 gene mutations)
>  Myoclonus-dystonia: most common cause is  SGCE gene mutations
 Dystonia associated with neurodegenerative disorders 
>  Autosomal dominant 
 • Huntington disease
 • Machado-Joseph disease (SCA3)
 • Basal ganglia calcifications syndromes
 • SCAs
 • Neuroferritinopathy
>  Autosomal recessive 
 • Juvenile Parkinson’s disease
 • Wilson’s disease
 • Neuroacanthocytosis syndromes
 • Hallervorden-Spatz disease
 •  Neurodegeneration with brain iron accumulation syndromes 
(pantothenate kinase associated neurodegeneration, 
 PLA2G6 associated neurodegeneration, Kufor Rakeb 
syndrome, MPAN, BPAN, aceruloplasminemia)
 • Lysosomal storage disorders
 • Ataxia-Telangiectasia
 • Homocystinuria
>  Recessive X-linked 
 • Lubag disease
 • Lesh-Nyhan syndrome
 • Rett syndrome
>  Mitochondrial disorders 
 • Leber disease
 • MELAS
 • MERRF
 • Leigh’s disease
>  Parkinsonian syndromes 
 • Parkinson’s disease
 • Progressive Supranuclear Palsy
 • Cortico-basal syndrome
 • Multiple system atrophy
 Dystonia associated with acquired causes 
>  Medications 
 •  Dopaminergic (L-dopa, dopamine agonists), dopamine 
receptor blocking drugs (neuroleptics, prochlorperazine, 
metoclopramide), selective serotonin reuptake inhibitors, 
MAO inhibitors, antiepileptic drugs, ergots, flecainide, 
cocaine, ranitidine, calcium antagonists, anaesthetic 
agents.
>  Toxins 
 •  Manganese, carbon monoxide, carbon disulfide, cyanide, 
methanol, disulfiram
>  Infectious, post-infectious and inflammatory diseases 
 •  Subacute sclerosing panencephalopathy, Reye’s syndrome, 
viral encephalitis, Creutzfeld-Jakob disease, systemic lupus 
erythematosus, Antiphospholipid syndrome, Sjogren’s syndrome.
>  CNS lesion 
 •  Brain tumour, Stroke, Hypoxia, Intracranial haemorrhage, 
CNS trauma, congenital malformations, cervical cord lesions.
>  Perinatal cerebral injury 
 •  Cerebral palsy, delayed-onset dystonia, perinatal hypoxia, 
kernicterus.
 Functional dystonia 
 BPAN = beta-propeller protein-associated neurodegeneration; CNS = central nervous 
system; GTP = guanosine triphosphate; MAO = monoamine oxydase; MELAS = 
mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; 
MERRF = myoclonic epilepsy with ragged red fibers; MPAN = mitochondrial 
membrane protein-associated neurodegeneration;  SCAs = spinocerebellar ataxias. 
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the disease progresses, global cognitive decline appears, initially 
mainly manifesting as loss of cognitive flexibility, executive 
dysfunction, memory and attention deficits and reduced 
psychomotor speed. 37,38 
 A number of HD lookalikes have been described. Within 
this group,  c9orf72 expansions, spanning across all age groups, 
have recently been described as the most commonly identified 
genetic cause (1.95%), followed by spinocerebellar ataxia type 
17, Huntington’s disease-like 2, Friedreich ataxia, and inherited 
prion disease (HDL-1). The group of HD phenocopies is in 
continuous expansion. 39 
 Among the forms of chorea beginning in youth and showing 
a slowly progressive or apparently non-progressive course, there 
have been recent advances in the characterisation of benign 
hereditary chorea, which was confirmed to be genetically 
heterogeneous. This condition is mostly caused by  NKX2.1 
autosomal dominant mutations, which should be screened 
for where there is a history of neonatal hypotonia, motor 
developmental delay, and early-onset hyperkinetic movement 
disorder (often generalised chorea and/or dystonia) with 
possible comorbid lung or thyroid symptoms. 40 Early-onset 
chorea and dystonia can also be distinguishing features of the 
recently identified autosomal dominant inherited adenylate 
cyclase-5 ( ADCY5 ) mutations. 41 
 Treatment 
 The treatment of chorea aims to reverse treatable conditions, 
followed or accompanied by symptomatic management. 
Symptomatic pharmacological management is necessary when 
chorea is not fully reversible (eg neurodegenerative or vascular 
causes) or if aetiologic treatment is complex and the patient 
needs fast and effective improvement. Three main classes of 
medications are used to alleviate chorea: 
1  D2 dopamine receptor blockers (antipsychotics) 
2  tetrabenazine, indicated to treat chorea in HD and tardive 
choreiform dyskinesias 
3  antiepileptic agents (mainly carbamazepine and valproic 
acid). 
 In patients with chorea and severe behavioural symptoms (eg 
psychosis, depression and aggressive behaviour) antipsychotics 
may be favoured, whereas tetrabenazione may be more difficult 
to manage in the presence of severe depression with suicidal 
risk. A combination of antipsychotics and tetrabenazine can 
be considered, if safe, when monotherapy is unsuccessful. 
Antiepileptic drugs like carbamazepine and valproate are 
less effective anti-chorea agents, with the exception of 
paroxysmal kinesigenic chorea, which responds dramatically to 
carbamazepine. 42,43 
 Surgical treatment (either ablative or DBS) of chorea is 
still at an experimental level and it should be used in select 
cases refractory to pharmacological treatments. Evidence 
supporting surgical treatment of chorea is quite limited and 
focuses mainly on HD and neuroacanthocytosis syndromes. 44 
The GPi is the target of deep brain stimulation for relieving 
chorea. However, long-term outcomes are still uncertain, 
considering the progressive course of these conditions. DBS of 
the GPi in tardive choreiform dyskinesias is supported by recent 
promising evidence. 45 
 Conclusion 
 Because of the wide variety of different aetiological causes of 
movement disorders and a large number of different forms 
of clinical presentation, it is important to use a step-by-step 
organised approach to patients with a movement disorder. The 
first step is to identify whether it is a hypo- or hyperkinetic 
movement disorder and, if the latter, which particular form 
of dyskinesia. Age and distribution and whether there are 
associated other signs or clinical features is to be noted. ■ 
 Supplementary material 
 Additional supplementary material may be found in the online version 
of this article at  www.clinmed.rcpjournal.org/ : 
 S1 – Clinical approach to chorea 
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